Starling Oncology, Inc. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
Starling Oncology, Inc. (DFPH) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$16.11 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2024-11-13
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-09-30 was -$16.11M.
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-06-30 was -$15.48M.
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-03-31 was -$19.89M.
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-12-31 was -$18.75M.
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was -$83.07M.
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was -$20.57M.
- Starling Oncology, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2021 was -$10.93M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$16.11M 10-Q · filed 2024-11-13 | -$31.59M derived: sum of 2 quarters · filed 2024-11-13 | -$51.48M 10-Q · filed 2024-11-13 | -$70.23M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | -$15.48M 10-Q · filed 2024-08-13 | -$35.37M 10-Q · filed 2024-08-13 | -$54.12M derived: sum of 3 quarters · filed 2024-08-13 | -$71.54M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | -$19.89M 10-Q · filed 2024-05-14 | -$38.64M derived: sum of 2 quarters · filed 2024-05-14 | -$56.06M derived: sum of 3 quarters · filed 2024-11-13 | -$72.96M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | -$18.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$36.17M derived: sum of 2 quarters · filed 2024-11-13 | -$53.07M derived: sum of 3 quarters · filed 2024-11-13 | -$83.07M 10-K · filed 2024-03-28 |
| 2023-09-30 | -$17.42M 10-Q · filed 2024-11-13 | -$34.32M derived: sum of 2 quarters · filed 2024-11-13 | -$64.31M 10-Q · filed 2024-11-13 | -$82.01M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$16.90M 10-Q · filed 2024-08-13 | -$46.90M 10-Q · filed 2024-08-13 | -$64.59M derived: sum of 3 quarters · filed 2024-08-13 | -$81.23M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$30.00M 10-Q · filed 2024-05-14 | -$47.69M derived: sum of 2 quarters · filed 2024-05-14 | -$64.33M derived: sum of 3 quarters · filed 2024-05-14 | -$69.85M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$34.34M derived: sum of 2 quarters · filed 2024-03-28 | -$39.85M derived: sum of 3 quarters · filed 2024-03-28 | -$20.57M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$16.64M 10-Q · filed 2023-11-08 | -$22.16M derived: sum of 2 quarters · filed 2023-11-08 | -$2.88M 10-Q · filed 2023-11-08 | -$13.03M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$5.52M 10-Q · filed 2023-08-09 | $13.77M 10-Q · filed 2023-08-09 | $3.61M derived: sum of 3 quarters · filed 2023-08-09 | $633.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $19.29M 10-Q · filed 2023-05-10 | $9.13M derived: sum of 2 quarters · filed 2023-05-10 | $6.15M derived: sum of 3 quarters · filed 2023-05-10 | $9.36M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$10.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$13.14M derived: sum of 2 quarters · filed 2023-03-16 | -$9.93M derived: sum of 3 quarters · filed 2023-03-16 | -$10.93M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$2.98M 10-Q · filed 2022-11-09 | $225.00K derived: sum of 2 quarters · filed 2022-11-09 | -$771.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.21M 10-Q · filed 2022-08-09 | $2.21M 10-Q · filed 2022-08-09 |